^
BIOMARKER:

DDR

DDR
Prostate Cancer
durvalumab
Sensitive: C2 – Inclusion Criteria
DDR
Cervical Cancer
BAY1895344
Sensitive: C2 – Inclusion Criteria
DDR
NSCLC
PD-L1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
DDR
NSCLC
atezolizumab
Sensitive: C3 – Early Trials
DDR
Cholangiocarcinoma
lenvatinib + toripalimab
Sensitive: C3 – Early Trials
DDR
CRC
CAPOX
Sensitive: C3 – Early Trials
DDR
CRC
FOLFOX
Sensitive: C3 – Early Trials
DDR
CRC
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Triple Negative Breast Cancer
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
DDR
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
DDR
Prostate Cancer
olaparib
Sensitive: C3 – Early Trials
DDR
Prostate Cancer
abiraterone acetate
Resistant: C3 – Early Trials
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C3 – Early Trials
DDR
NSCLC
ABT-888
Sensitive: C3 – Early Trials
DDR
RCC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
DDR
Breast Cancer
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
DDR
Prostate Cancer
talazoparib
Sensitive: C3 – Early Trials
DDR
Pancreatic Cancer
olaparib
Sensitive: C3 – Early Trials
DDR
HCC
FOLFOX
Sensitive: C3 – Early Trials
DDR
Soft Tissue Sarcoma
olaparib
Sensitive: C3 – Early Trials
DDR
Prostate Cancer
olaparib + abiraterone acetate
Sensitive: C4 – Case Studies